07 May 2020 - The Australian share market closed 0.4 per cent down. Australian Performance of Services Index plunged 11.6 points.
07 May 2020 - The Australian share market opened lower this morning and is now trading 0.6 per cent lower at noon. Link (ASX:LNK) says areas of its business has been hit by the COVID-19 pandemic.
07 May 2020 - CSL (ASX:CSL) has announced a new $US750 million ($1.17 billion) private placement.
07 May 2020 - BHP (ASX:BHP) has appointed two new independent non-executive directors - Dion Weisler and Xiaoqun Clever.
07 May 2020 - Aged care homes operator Oceania Healthcare (ASX:OCA) has reported that no COVID-19 have been recorded in their facilities.
07 May 2020 - G8 Education’s (ASX:GEM) CEO and Managing Director Mr Gary Carroll has taken a pay cut.
07 May 2020 - Following mixed leads from US markets, the ASX looks set to open lower this morning. The S&P 500 and Dow Jones Industrial Average indexes closed lower, while IT and consumer discretionary sectors kept the Nasdaq in the green. Back home, close to 730,000 employers have so far signed up for the JobKeeper allowance, covering around 4.7 million employees. On the commodities front, oil has dropped and gold is also down. OceanaGold (ASX:OGC) released their first...
06 May 2020 - The ASX failed to rise into positive territory today closing 0.4% lower. Nearmap (ASX:NEA) shares are on the rise as are Appen (ASX:APX). Shares in National Storage REIT (ASX:NSR) are down – they completed their $300m institutional placement today. The Goodman Group (ASX:GMG) today announced the appointment of Mark G. Johnson as an Independent Director.
06 May 2020 - The ASX dropped at the open and is now tracking 1.1% lower at noon. Nearmap (ASX:NEA) shares are on the rise as are Domain Holdings (ASX:DHG). The Australian dollar has risen to US64.33 cents. As for the sectors, utilities are up and financials, down. ALS (ASX:ALQ) reports less than 10% of their global laboratory network has been adversely impacted by shutdowns due to COVID-19.
06 May 2020 - Mesoblast (ASX:MSB) today announced that the first patients have been dosed in the 300-patient randomized placebo-controlled Phase 2/3 trial in the United States of Mesoblast’s remestemcel-L in COVID-19 infected patients.
